Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-942-2935
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.89 million
Profitability
Miscellaneous
Employees61
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions
What is Aeglea Bio Therapeutics' stock symbol?
Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."
How were Aeglea Bio Therapeutics' earnings last quarter?
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) announced its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.07. View Aeglea Bio Therapeutics' Earnings History.
When is Aeglea Bio Therapeutics' next earnings date?
What price target have analysts set for AGLE?
3 brokerages have issued twelve-month price targets for Aeglea Bio Therapeutics' shares. Their forecasts range from $14.00 to $20.00. On average, they expect Aeglea Bio Therapeutics' share price to reach $17.00 in the next year. This suggests a possible upside of 109.6% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics.
What is the consensus analysts' recommendation for Aeglea Bio Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics.
What are Wall Street analysts saying about Aeglea Bio Therapeutics stock?
Here are some recent quotes from research analysts about Aeglea Bio Therapeutics stock:
- 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development." (6/3/2019)
- 2. According to Zacks Investment Research, "Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. " (1/8/2019)
Has Aeglea Bio Therapeutics been receiving favorable news coverage?
News headlines about AGLE stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Aeglea Bio Therapeutics.
Who are some of Aeglea Bio Therapeutics' key competitors?
Some companies that are related to Aeglea Bio Therapeutics include Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Axsome Therapeutics (AXSM), ZIOPHARM Oncology (ZIOP), ANI Pharmaceuticals (ANIP), Vanda Pharmaceuticals (VNDA), Alder Biopharmaceuticals (ALDR), Kura Oncology (KURA), Arvinas (ARVN), Eagle Pharmaceuticals (EGRX), OrganiGram (OGI), Cytokinetics (CYTK) and CannTrust (CNTTF).
What other stocks do shareholders of Aeglea Bio Therapeutics own?
Who are Aeglea Bio Therapeutics' key executives?
Aeglea Bio Therapeutics' management team includes the folowing people:
- Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)
- Mr. Charles N. York II, CFO & VP (Age 42)
- Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)
- Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)
- Mr. Eugene Sackett, VP of HR
When did Aeglea Bio Therapeutics IPO?
(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.
Who are Aeglea Bio Therapeutics' major shareholders?
Aeglea Bio Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Aisling Capital Management LP (4.48%), Vanguard Group Inc. (3.82%), Marshall Wace LLP (2.28%), Renaissance Technologies LLC (1.89%) and Northern Trust Corp (0.81%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn, Bioventures Ltd Novartis and Charles N York II. View Institutional Ownership Trends for Aeglea Bio Therapeutics.
Which institutional investors are selling Aeglea Bio Therapeutics stock?
Which institutional investors are buying Aeglea Bio Therapeutics stock?
AGLE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Marshall Wace LLP, Artal Group S.A., Renaissance Technologies LLC, Aisling Capital Management LP, Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn and Charles N York II. View Insider Buying and Selling for Aeglea Bio Therapeutics.
How do I buy shares of Aeglea Bio Therapeutics?
Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeglea Bio Therapeutics' stock price today?
One share of AGLE stock can currently be purchased for approximately $8.11.
How big of a company is Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics has a market capitalization of $234.30 million and generates $3.89 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.View Additional Information About Aeglea Bio Therapeutics.
What is Aeglea Bio Therapeutics' official website?
How can I contact Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]
MarketBeat Community Rating for Aeglea Bio Therapeutics (NASDAQ AGLE)
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.
